Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Rhea-AI Summary

Gain Therapeutics (Nasdaq: GANX) will participate in the 2025 Maxim Growth Summit on October 22–23, 2025 at The Hard Rock Hotel NYC.

Gene Mack, President and CEO, will join a live discussion on October 22 titled “Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutics Categories.” The panel will cover innovative approaches for neurodegenerative diseases that are currently in active clinical trials. Investors or analysts interested in a meeting with Gain management are instructed to contact their Maxim sales representative to schedule.

BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it will participate in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC.

Gene Mack, President and CEO of Gain, will be participating in a live discussion, “Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutics Categories”, on October 22nd. The panel will include discussion about innovative approaches for a range of neurogenerative diseases that are in active clinical trials,

If you are interested in meeting with Gain management, please contact your Maxim sales representative to schedule.

About the Maxim Growth Summit

This event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.

Keynote speakers are to include Larry Kudlow (Broadcaster, Fox News) and Christopher Ruddy (CEO, Newsmax Media). The conference will also feature roundtable discussions with CEOs from small and mid-cap companies, moderated by Maxim Research Analysts. Roundtable discussions will cover a range of sectors, including biotechnology, stem cell therapy, ophthalmology, artificial intelligence, energy and mining, drones, and more.

For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2025-growth-summit.

About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.

Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.

Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company’s current or future product candidates including GT-02287; expectations regarding the completion and timing of results from a Phase 1b clinical study for GT-02287; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287; the timing of any submissions to the FDA or other regulatory bodies and agencies; and the potential therapeutic and clinical benefits of the Company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information, future events or otherwise.

Investors:
Gain Therapeutics, Inc. 
Apaar Jammu 
Manager, Investor Relations and Public Relations
ajammu@gaintherapeutics.com

LifeSci Advisors LLC
Chuck Padala
Managing Director
chuck@lifesciadvisors.com

Media:
Russo Partners LLC
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256

FAQ

When is Gain Therapeutics (GANX) presenting at the 2025 Maxim Growth Summit?

Gain management will attend the summit on October 22–23, 2025, with the CEO speaking on October 22.

What topic will Gene Mack of Gain Therapeutics (GANX) discuss on October 22, 2025?

Gene Mack will participate in the Neurodegenerative Diseases Panel focusing on under‑the‑radar innovators and active clinical trial approaches.

How can investors schedule a meeting with Gain Therapeutics (GANX) management at the Maxim summit?

Investors should contact their Maxim sales representative to request and schedule a meeting with Gain management.

Will the panel discuss Gain Therapeutics' clinical programs currently in trials?

The panel will include discussion of innovative approaches for neurodegenerative diseases that are in active clinical trials.

Where is the 2025 Maxim Growth Summit taking place for Gain Therapeutics (GANX)?

The summit is at The Hard Rock Hotel NYC from October 22 to 23, 2025.